ClinicalTrials.gg
Not yet recruitingNCT07631897ALT VS TLEUpdated Jun 8, 2026

Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens

A Phase 4 interventional study of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets and Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets in HIV, Art Therapy and TB - Tuberculosis, sponsored by Shanghai Public Health Clinical Center. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Shanghai Public Health Clinical Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine/Lamivudine/Tenofovir and Efavirenz/Lamivudine/Tenofovir regimens combined with rifampicin and isoniazid-based anti-tuberculosis therapy in HIV-infected patients with active tuberculosis.

Participants are divided into two groups to compare the virological suppression rate and immunological efficacy between the two antiretroviral regimens. All subjects will receive continuous antiretroviral medication and anti-tuberculosis drugs under medical supervision throughout the study.

02

Conditions studied

  • HIV
  • Art Therapy
  • TB - Tuberculosis

Browse trials for

03

In context

Latent Tuberculosis

200 studies on the registry are indexed under Latent Tuberculosis; 49 are open to participants now.

This study's planned enrollment of 60 is below the median of 300 across 111 interventional studies indexed under Latent Tuberculosis.

Browse Latent Tuberculosis studies →

Lead sponsor

Shanghai Public Health Clinical Center is the lead sponsor of 38 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 65 years;
  • Body weight ≥ 40 kg with ranging from 18.5 to 30 kg/m²;
  • Treatment-naïve patients with -1 infection who are planned to initiate antiretroviral therapy;
  • Diagnosed with active Mycobacterium tuberculosis infection and receiving anti-tuberculosis regimen containing rifampicin and isoniazid;
  • CD4⁺ T cell count ≥ 25 cells/μL;
  • HIV RNA viral load \< 500,000 copies/mL;
  • Subjects who can fully understand the nature, methods and potential adverse reactions of this trial, comply with the requirements stated in the form, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Subjects with allergic constitution or a history of allergy to the study drugs and ;
  • Those with a history of drug addiction, substance abuse, or chronic alcoholism;
  • Pregnant or lactating women; women of who cannot adopt effective measures (e.g., contraceptive diaphragm, condom, intrauterine device, partner vasectomy), or whose sexual partners fail to implement effective contraception;
  • Subjects who have used drugs with moderate to high drug drug interaction potential with the study drugs (excluding anti tuberculosis drugs) within 2 weeks prior to formal enrollment and ART initiation (only applicable to the pre trial phase);
  • Those who are unable to receive oral anti tuberculosis treatment during antiretroviral therapy;
  • Subjects with baseline drug resistance test results showing resistance to NNRTIs, 3TC or TDF;
  • Those with resistance to one or more anti tuberculosis drugs;
  • Subjects diagnosed or tentatively diagnosed with tuberculous meningitis;
  • Patients complicated with other severe opportunistic infections besides Mycobacterium tuberculosis infection;
  • Abnormal liver function: (ALT)/aspartate transaminase (AST) > 3× with clinical symptoms, or > 5×ULN without symptoms; total (TBil) > 2×ULN;
  • Impaired renal function: estimated (eGFR) calculated by the CKD EPI formula \< 60 mL/min/1.73 m²;
  • Subjects complicated with tumors, severe neurological or psychiatric diseases, metabolic disorders, gastrointestinal diseases or other comorbidities that, in the investigator's judgment, may affect their participation and completion of the study;
  • Any other conditions deemed inappropriate for enrollment by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    TLE group

    Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment consisting of rifampicin and isoniazid. The regimen is Efavirenz 400 mg, Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg, one tablet of each taken once daily.

    Drug: Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets

  • Experimental
    ALT group

    Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment with rifampicin and isoniazid. The regimen is Ainuovirine 150mg, Lamivudine 300mg and Tenofovir 300mg, one tablet each time, once daily.

    Drug: Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets

Interventions

  • DrugAinuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets

    Drug pages: AinuovirineStudies of AinuovirineAinuovirine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LamivudineStudies of LamivudineLamivudine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TenofovirStudies of TenofovirTenofovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment with rifampicin and isoniazid. The regimen is Ainuovirine 150mg, Lamivudine 300mg and Tenofovir 300mg, one tablet each time, once daily.

  • DrugTenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets

    Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment consisting of rifampicin and isoniazid. The regimen is Efavirenz 400 mg, Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg, one tablet of each taken once daily.

06

What researchers measure

Primary outcomes

  1. Viral suppression rates of two antiretroviral therapy(ART) regimens at week 48

    Percentage of HIV RNA virological suppression (HIV RNA viral load \<50 copies/mL) in two groups treated with Ainuovirine-based regimen or TLE regimen for 48 weeks

    Time frame: at week 48

Secondary outcomes

  1. Immunological efficacy (CD4+ T cell count) of the two groups at week 48

    Time frame: at week 48

  2. ART treatment failure rate of the two groups

    Time frame: at week 48

  3. Evaluate the anti-tuberculosis treatment outcomes of two groups, with primary indicators of cure rate and treatment failure rate

    Time frame: at week 48

  4. Incidence rates of all-grade adverse events and grade ≥3 adverse events in the two groups

    Time frame: through study completion, about 48 weeks

  5. Types and constituent ratios of adverse events above grade 1 in the two groups

    Time frame: through study completion, about 48 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2026
First posted
Jun 8, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07631897
Lead sponsor
Shanghai Public Health Clinical Center
Responsible party
Jun Chen, MD (Chief Physician, Shanghai Public Health Clinical Center) — Principal investigator
First posted
Jun 8, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 8, 2026

Study contacts

Jun Chen
Contact
chenjun@shaphc.org
021-37990333
Ling Gu
Contact
guling@shaphc.org
021-37990333

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ainuovirine · Lamivudine · Tenofovir

Start the discussion